Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

60;

ANA773

  • Planned Phase IIa Study – In late 2010 the Company announced plans to resume development of ANA773 in HCV as a complement to DAAs in potential all oral regimens. The next planned study is a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a DAA in subsequent cohorts. Anadys intends to conduct this Phase IIa study of ANA773 in Europe and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.  ANA773 is the Company's oral, small-molecule inducer of endogenous interferons that acts via the TLR7 pathway.
  • 2011 Anticipated Milestones – Anadys intends to commence the ANA773 28-day study during the second quarter of 2011 and expects to receive 4 week viral load data for ANA773 plus ribavirin in the fourth quarter of 2011.

  • Financial Results and HighlightsAs of December 31, 2010, Anadys' cash, cash equivalents and securities available-for-sale totaled $38.0 million compared to $20.5 million as of December 31, 2009.  The increase in cash, cash equivalents and securities available-for-sale reflects the receipt of net proceeds of $34.7 million from the Company's completed equity financings in June and October of 2010, partially offset by the Company's cash utilization during the year to fund operations.

    Total operating expenses were $4.5 million for the fourth quarter of 2010, compared to $5.6 million for the fourth quarter of 2009.  Included as a component of operating expenses were non-cash, share-based expenses of $0.3 million and $0.4 million for the fourth quarter of 2010 and 2009, respectively.

    Research and development expenses were $2.8 million for the fourth quarter of 2010, compared to $4.0 million for the fourth quarter of 2009.  Included as an offset to research and development expenses in the fourth quarter of
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
    (Date:12/19/2014)... , Dec. 19, 2014 Research and Markets ... addition of the "Technology Innovations in Smart ... http://photos.prnewswire.com/prnh/20130307/600769 ... Smart Fabrics" offers a detailed assessment on technological ... Key Findings: 1. The Smart ...
    (Date:12/19/2014)... (PRWEB) December 18, 2014 Reports from ... the United States suffer from one or more chronic ... or cancer. Medication can address some of these diseases, ... activities that many sufferers face. While implanted nerve stimulation ... stimulate the whole nerve, which can induce side effects. ...
    (Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... biomaterial market will grow moderately through 2023 as the ... growing awareness of dental biomaterials all spur procedure volumes. ... as China and ... dental procedures within reach for a larger proportion of ...
    Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Technology Innovations in Smart Fabrics (Technical Insights) 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
    ... FT. LAUDERDALE, Fla., July 30 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials announced today that a ... provide eClinical solutions in connection with two of the CRO,s ... 700 subjects. Additional details were not disclosed. Phase IV studies ...
    ... , RALEIGH, N.C. , July 30 SmartGene, ... of genetic data, today announced that it has entered into an ... technology and integrated Web-based services to support more rapid and precise ... , Some bacteria and fungi do not grow quickly ...
    ... 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology ... based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... with its vaccine candidate for the Influenza A (H1N1) ... a single dose of 5 micrograms induced a positive ...
    Cached Biology Technology:Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies 2SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3
    (Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - ... report to their offering. ... of AuthenTec in July 2012, Apple introduced the ... is currently the only device of Apple incorporating ...
    (Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
    (Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
    Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
    ... -- Look out, Indiana Jones. Dan Shain ... to frozen glaciers and the steamy Amazon planned, all ... cinematic icon, Shain, an associate professor of biology at ... returns home with treasure. He,s mined for ice ...
    ... Western Reserve University have developed a technique that has ... within hours, as opposed to the two days it ... mice, drug delivery time from injection to the cancer ... Using this as a model for potential human use, ...
    ... is a significant challenge for researchers. That challenge is prompting ... that data and to make it readily available. The ... Disease has created a new collaboration tool, WikiPathways to focus ... "Biological pathways connect genes and proteins in systems that ...
    Cached Biology News:Rutgers biologist to study worms in Amazon, glaciers 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Gladstone scientists create Wikipathways to foster research collaboration 2
    ... This antibody is generated from rabbits immunized ... within aa 50~150 of human PLAU. Purified ... 0.09% (W/V) sodium azide. This antibody is ... eluted out with both high and low ...
    ... is a compact, lightweight, high current power supply ... 2500 milliamps. It is an excellent choice for ... It is also ideal for all types of ... set to automatically end a run and wil ...
    ... For use in Refrigerated Vapor Trap ... Vacuum Source (UVS) Models UVS400, UVS400A and ... polymer suitable for use for temperatures ranging ... has excellent thermal stability and does not ...
    ... proteomics demands the detection of very small ... the AXIMA-CFRplus with improved resolution (20,000) and ... increased confidence in protein identification. The AXIMA-CFRplus ... automated sample target handling and the ability ...
    Biology Products: